CoChat

Cellular senescence as a therapeutic target to improve renal transplantation outcome

Open access
van Willigenburg, Hester, de Keizer, Peter L.J., de Bruin, Ron W.F. · 2018 · Pharmacological Research
Cited by 38

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

• Senescent cells secrete a range of pro-inflammatory factors and growth factors. • Chronically present senescent cells can negatively influence local milieu and organ function. • Senescent cells in renal grafts impair transplantation outcome. • Renal transplantation induces senescence. • The use of anti-senescence compounds to improve renal transplantation outcome is proposed. Kidney transplants from aged donors are more vulnerable to ischemic injury, suffer more from delayed graft function and have a lower graft survival compared to kidneys from younger donors. On a cellular level, aging results in an increase in cells that are in a permanent cell cycle arrest, termed senescence, which secrete a range of pro-inflammatory cytokines and growth factors. Consequently, these senescent cells negatively influence the local milieu by causing inflammaging, and by reducing the regenerative capacity of the kidney. Moreover, the oxidative damage that is inflicted by ischemia-reperfusion injury during transplantation can induce senescence and accelerate aging. In this review, we describe recent developments in the understanding of the biology of aging that have led to the development of a new class of therapeutic agents aimed at eliminating senescent cells. These compounds have already shown to be able to restore tissue homeostasis in old mice, improve kidney function and general health- and lifespan. Use of these anti-senescence compounds holds great promise to improve the quality of marginal donor kidneys as well as to remove senescent cells induced by ischemia-reperfusion injury. Altogether, senescent cell removal may increase the donor pool, relieving the growing organ shortage and improve long-term transplantation outcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.phrs.2018.02.015

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Research works printed but not linked: 67

  1. Hazra, 2017, Determinants of health care costs in the senior elderly: age, comorbidity, impairment, or proximity to death?, Eur. J. Heal. Econ., 1
  2. Kontis, 2017, Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble, Lancet (Lond. Engl.), 389, 1323, 10.1016/S0140-6736(16)32381-9 · DOI · Paper page
  3. van Oostrom, 2014, Multimorbidity of chronic diseases and health care utilization in general practice, BMC Fam. Pract., 15, 61, 10.1186/1471-2296-15-61 · DOI · Paper page
  4. Hill, 2016, Global prevalence of chronic kidney disease – a systematic review and meta-analysis, PLoS One, 11, e0158765, 10.1371/journal.pone.0158765 · DOI · Paper page
  5. Weinstein, 2010, The aging kidney: physiological changes, Adv. Chronic Kidney Dis., 17, 302, 10.1053/j.ackd.2010.05.002 · DOI · Paper page
  6. Stevens, 2010, Chronic kidney disease and end-stage renal disease in the elderly population: current prevalence, future projections, and clinical significance, Adv. Chronic Kidney Dis., 17, 293, 10.1053/j.ackd.2010.03.010 · DOI · Paper page
  7. Heerspink, 2013, Novel drugs and intervention strategies for the treatment of chronic kidney disease, Br. J. Clin. Pharmacol, 76, 536, 10.1111/bcp.12195 · DOI
  8. Thiruchelvam, 2011, Renal transplantation, BMJ, 343, d7300, 10.1136/bmj.d7300 · doi:10.1136/bmj.d7300
  9. Agarwal, 2016, Defining end-stage renal disease in clinical trials: a framework for adjudication: table 1, Nephrol. Dial. Transplant., 31, 864, 10.1093/ndt/gfv289 · DOI
  10. Lim, 2013, Outcomes of kidney transplantation from older living donors, Transplant. J., 95, 106, 10.1097/TP.0b013e318277b2be · DOI
  11. Slegtenhorst, 2014, Mechanisms and consequences of injury and repair in older organ transplants, Transplantation, 97, 1091, 10.1097/TP.0000000000000072 · DOI
  12. Tasaki, 2014, Effect of donor–recipient age difference on long-term graft survival in living kidney transplantation, Int. Urol. Nephrol., 46, 1441, 10.1007/s11255-014-0655-8 · doi:10.1007/s11255-014-0655-8
  13. Oberhuber, 2012, Donor age-specific injury and immune responses, Am. J. Transplant., 12, 38, 10.1111/j.1600-6143.2011.03798.x · DOI
  14. Kurschat, 2016, Nierentransplantation im alter, Z. Gerontol. Geriatr., 49, 488, 10.1007/s00391-016-1118-x · DOI
  15. Braun, 2012, Cellular senescence limits regenerative capacity and allograft survival, J. Am. Soc. Nephrol., 23, 1467, 10.1681/ASN.2011100967 · DOI · Paper page
  16. Broude, 2007, p21Waf1/Cip1/Sdi1 mediates retinoblastoma protein degradation, Oncogene, 26, 6954, 10.1038/sj.onc.1210516 · DOI
  17. Coppé, 2010, The senescence-associated secretory phenotype: the dark side of tumor suppression, Annu. Rev. Pathol., 5, 99, 10.1146/annurev-pathol-121808-102144 · DOI · Paper page
  18. Hoffmann, 2015, NK cells of kidney transplant recipients display an activated phenotype that is influenced by immunosuppression and pathological staging, PLoS One, 10, e0132484, 10.1371/journal.pone.0132484 · DOI
  19. Morteau, 2010, Renal transplant immunosuppression impairs natural killer cell function in vitro and in vivo, PLoS One, 5, e13294, 10.1371/journal.pone.0013294 · DOI
  20. Franceschi, 2014, Chronic inflammation (Inflammaging) and its potential contribution to age-associated diseases, J. Gerontol. Ser. A Biol. Sci. Med. Sci., 69, 10.1093/gerona/glu057 · DOI · Paper page
  21. Bonventre, 2011, Cellular pathophysiology of ischemic acute kidney injury, J. Clin. Invest., 121, 4210, 10.1172/JCI45161 · DOI · Paper page
  22. Salvadori, 2015, Update on ischemia-reperfusion injury in kidney transplantation: pathogenesis and treatment, World J. Transplant., 5, 52, 10.5500/wjt.v5.i2.52 · DOI · Paper page
  23. McGlynn, 2009, Cellular senescence in pretransplant renal biopsies predicts postoperative organ function, Aging Cell, 8, 45, 10.1111/j.1474-9726.2008.00447.x · DOI · Paper page
  24. Melk, 2008, Effects of donor age and cell senescence on kidney allograft survival, Am. J. Transplant., 9, 114, 10.1111/j.1600-6143.2008.02500.x · DOI · Paper page
  25. Boonstra, 2004, Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells, Gene, 337, 1, 10.1016/j.gene.2004.04.032 · DOI · Paper page
  26. Hochegger, 2007, p21 and mTERT are novel markers for determining different ischemic time periods in renal ischemia-reperfusion injury, Am. J. Physiol. Renal Physiol., 292, F762, 10.1152/ajprenal.00084.2006 · DOI · Paper page
  27. Kailong, 2007, P53-Rb signaling pathway is involved in tubular cell senescence in renal ischemia/reperfusion injury, Biocell, 31, 213, 10.32604/biocell.2007.31.213 · DOI
  28. Seikrit, 2013, Biological responses to PDGF-AA versus PDGF-CC in renal fibroblasts, Nephrol. Dial. Transplant., 28, 889, 10.1093/ndt/gfs509 · doi:10.1093/ndt/gfs509
  29. Boor, 2014, PDGF and the progression of renal disease, Nephrol. Dial. Transplant., 29, i45, 10.1093/ndt/gft273 · DOI
  30. Lee, 2012, INK4a deletion results in improved kidney regeneration and decreased capillary rarefaction after ischemia-reperfusion injury, AJP Renal Physiol., 302, F183, 10.1152/ajprenal.00407.2011 · DOI · Paper page
  31. Nishioka, 2014, The cyclin-dependent kinase inhibitor p21 is essential for the beneficial effects of renal ischemic preconditioning on renal ischemia/reperfusion injury in mice, Kidney Int., 85, 871, 10.1038/ki.2013.496 · DOI
  32. DiRocco, 2014, CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury, AJP Renal Physiol., 306, F379, 10.1152/ajprenal.00475.2013 · DOI · Paper page
  33. Baar, 2017, Maintenance and repair of an aging life cycle, Oncotarget, 1–2
  34. Requião-Moura, 2015, Ischemia and reperfusion injury in renal transplantation: hemodynamic and immunological paradigms, Einstein, 13, 129, 10.1590/S1679-45082015RW3161 · DOI
  35. Dong, 2017, Alleviation of senescence and epithelial-mesenchymal transition in aging kidney by short-term caloric restriction and caloric restriction mimetics via modulation of AMPK/mTOR signaling, Oncotarget, 8, 16109, 10.18632/oncotarget.14884 · DOI
  36. Ning, 2013, Short-term calorie restriction protects against renal senescence of aged rats by increasing autophagic activity and reducing oxidative damage, Mech. Ageing Dev., 134, 570, 10.1016/j.mad.2013.11.006 · DOI
  37. Trepanowski, 2011, Impact of caloric and dietary restriction regimens on markers of health and longevity in humans and animals: a summary of available findings, Nutr. J., 10, 107, 10.1186/1475-2891-10-107 · DOI · Paper page
  38. van Ginhoven, 2010, Preoperative fasting induced protection against renal ischemia/reperfusion injury is independent of ghrelin in mice, Nutr. Res., 30, 865, 10.1016/j.nutres.2010.09.014 · DOI
  39. Jongbloed, 2014, Preoperative fasting protects against renal ischemia-reperfusion injury in aged and overweight mice, PLoS One, 9, e100853, 10.1371/journal.pone.0100853 · DOI
  40. Mitchell, 2010, Short-term dietary restriction and fasting precondition against ischemia reperfusion injury in mice, Aging Cell, 9, 40, 10.1111/j.1474-9726.2009.00532.x · DOI · Paper page
  41. Shushimita, 2016, Protection against renal ischemia–reperfusion injury through hormesis? Dietary intervention versus cold exposure, Life Sci., 144, 69, 10.1016/j.lfs.2015.11.022 · DOI
  42. Tomé-Carneiro, 2013, Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence, Curr. Pharm. Des., 19, 6064, 10.2174/13816128113199990407 · DOI · Paper page
  43. An, 2016, Current understanding of metformin effect on the control of hyperglycemia in diabetes, J. Endocrinol., 228, R97, 10.1530/JOE-15-0447 · DOI · Paper page
  44. Wang, 2015, Metformin attenuated the inflammation after renal ischemia/reperfusion and suppressed apoptosis of renal tubular epithelial cell in rats, Acta Cir. Bras., 30, 617, 10.1590/S0102-865020150090000006 · DOI
  45. Arriola Apelo, 2016, An InhibiTOR of aging emerges from the soil of easter island, J. Gerontol. A. Biol. Sci. Med. Sci., 71, 841, 10.1093/gerona/glw090 · DOI · Paper page
  46. Li, 2017, A conserved NAD + binding pocket that regulates protein–protein interactions during aging, Science (80-.), 355, 1312, 10.1126/science.aad8242 · DOI · Paper page
  47. Yamamoto, 2014, Nicotinamide mononucleotide, an intermediate of NAD+ synthesis, protects the heart from ischemia and reperfusion, PLoS One, 9, e98972, 10.1371/journal.pone.0098972 · DOI · Paper page
  48. Osorio, 2012, Nuclear lamina defects cause ATM-dependent NF- B activation and link accelerated aging to a systemic inflammatory response, Genes Dev., 26, 2311, 10.1101/gad.197954.112 · DOI · Paper page
  49. Veroux, 2011, Sirolimus in solid organ transplantation: current therapies and new frontiers, Immunotherapy, 3, 1487, 10.2217/imt.11.143 · DOI
  50. Conchon, 2011, Dasatinib – clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia, Rev. Bras. Hematol. Hemoter., 33, 131, 10.5581/1516-8484.20110034 · DOI
  51. Zhou, 2014, Kidney-targeted drug delivery systems, Acta Pharm. Sin. B, 4, 37, 10.1016/j.apsb.2013.12.005 · doi:10.1016/j.apsb.2013.12.005
  52. van der Horst, 2006, FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP, Nat. Cell Biol., 8, 1064, 10.1038/ncb1469 · DOI · Paper page
  53. Hosaka, 2004, Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification, Proc. Natl. Acad. Sci. U. S. A., 101, 2975, 10.1073/pnas.0400093101 · DOI · Paper page
  54. Martins, 2016, Long live FOXO: unraveling the role of FOXO proteins in aging and longevity, Aging Cell, 15, 196, 10.1111/acel.12427 · DOI · Paper page
  55. Sawyer, 2017, Protein domain mimics as modulators of protein–Protein interactions, Acc. Chem. Res., 50, 1313, 10.1021/acs.accounts.7b00130 · DOI
  56. Workman, 2007, Chaperoning cell death: a critical dual role for Hsp90 in small-cell lung cancer, Nat. Chem. Biol., 3, 455, 10.1038/nchembio0807-455 · DOI
  57. Bendell, 2016, A phase 2 study of the hsp90 inhibitor AUY922 as treatment for patients with refractory gastrointestinal stromal tumors, Cancer Invest., 34, 265, 10.1080/07357907.2016.1193746 · DOI
  58. Seggewiss-Bernhardt, 2015, Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma, Cancer, 121, 2185, 10.1002/cncr.29339 · DOI
  59. Socinski, 2013, A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer, Clin. Cancer Rancer Res., 19, 3068, 10.1158/1078-0432.CCR-12-3381 · DOI · Paper page
  60. Ferry, 1996, Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition, Clin. Cancer Res, 2, 659
  61. Askari, 2012, The effect of quercetin supplementation on selected markers of inflammation and oxidative stress, J. Res. Med. Sci., 17, 637
  62. Tolcher, 2015, Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors, Cancer Chemother. Pharmacol., 76, 1025, 10.1007/s00280-015-2883-8 · DOI
  63. Vlahovic, 2014, A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors, Invest. New Drugs, 32, 976, 10.1007/s10637-014-0116-3 · DOI
  64. Homme, 2017, Un-reborn again, QOTSA, 6
  65. McKay, 2012, Kidney transplantation and the ageing immune system, Nat. Rev. Nephrol., 8, 700, 10.1038/nrneph.2012.242 · DOI
  66. Tang, 2016, Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations, Expert Opin. Drug Metab. Toxicol., 12, 555, 10.1517/17425255.2016.1170808 · DOI · Paper page
  67. Sagiv, 2013, Immunosurveillance of senescent cells: the bright side of the senescence program, Biogerontology, 14, 617, 10.1007/s10522-013-9473-0 · DOI · Paper page

Cited by

See all 38

Metadata

Authors
van Willigenburg, H., de Keizer, P. L. J., & de Bruin, R. W. F.
Venue
Pharmacological Research
Publisher
Elsevier BV
Published
2018-04
Volume
130
Pages
322-330
ISSN
1043-6618 (ISSN-L)
OpenAlex
W2790614466
Cited by
38
References
49
FWCI
2.23
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cellular senescence as a therapeutic target to improve renal transplantation outcome. https://app.cochat.ai/papers/10.1016/j.phrs.2018.02.015
The paper
van Willigenburg, H., de Keizer, P. L. J., & de Bruin, R. W. F. (2018). Cellular senescence as a therapeutic target to improve renal transplantation outcome. Pharmacological Research. https://doi.org/10.1016/j.phrs.2018.02.015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.